加强管理认知障碍司机的指导方针:从西方证据对亚洲适应的洞察力
Mei Leng Chan1, Dwee Wee Lim2, Khin Khin Win3
1Department of Occupational Therapy, Tan Tock Seng Hospital, Singapore.
Annals of the Academy of Medicine, Singapore
|November 7, 2024
概括
医生们很难评估痴呆症的司机. 对国际指导方针的审查显示,西方国家提供了全面的,基于证据的战略,可以帮助更新新加坡过时的痴呆症驱动指导方针.
科学领域:
- 老年学是一门学科.
- 神经学 神经学
- 公共卫生 公共卫生
背景情况:
- 全球痴呆症发病率正在上升,这增加了认知障碍司机发生车祸的风险.
- 医生在评估有风险的司机时面临挑战,不一致地遵守当前的指南.
研究的目的:
- 审查和比较管理认知障碍司机的国际指导方针.
- 确定评估和管理痴呆症患者驾驶的最佳实践.
主要方法:
- 一项范围审查确定了来自8个国家的11条指南 (美国,加拿大,英国,爱尔兰,比利时,澳大利亚,新西兰,新加坡).
- 指南进行了描述性比较,重点关注痴呆症驾驶评估和管理策略.
主要成果:
- 所有审查的指南都支持对患有痴呆症的非专业驾驶员进行驾驶评估和有条件许可.
- 西方的指导方针往往包括基于证据的方法,对轻度认知障碍的规定,以及从驾驶转型的指导.
- 新加坡目前的指导方针已经过时,缺乏对轻度认知障碍和停止驾驶的严格和具体指导.
结论:
- 来自西方国家的综合性,基于证据的指南为更新新加坡痴呆症驱动管理政策提供了宝贵的见解.
- 国际最佳实践可以为认知障碍司机制定更强大和更当前的指导方针提供信息.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98
Dementia
97
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
97
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448


